Treeway
Ronald van der Geest is a highly experienced professional in the pharmaceutical and life sciences industry, serving as Managing Partner and Co-Founder of 3D-PharmXchange since March 2010, where strategic and operational support is provided. Ronald also holds the position of Chief Development Officer and Founder at Onicor, focusing on innovative treatments for onychomycosis, and has been a Chief Development Officer at Treeway since August 2013, leading breakthrough therapies for ALS and Alzheimer's disease. Prior roles include Chief Development Officer at Protinhi Therapeutics, with a focus on drug development for dengue and zika viruses, and various leadership positions at Kinesis Pharma BV, InPEC BV, and Tibotec/Janssen, where drug development and project management were central. Ronald's extensive background in clinical pharmacology began with a PhD in Biopharmaceutical Sciences from Leiden University, complemented by early scientific research on drug delivery systems for Parkinson's Disease.
This person is not in any teams
Treeway
Treeway is a clinical-stage biotech company developing therapy for ALS, Alzheimer's Disease and other neurodegenerative diseases. Treeway has been formed by the words tree of life and pathway of a disease, for the founders the symbolic way towards a cure. We foresee that medication, research and care will change dramatically in the coming decades and patients will become an essential part of this process on their pursuit for cures in rare and common diseases. Everyone can make a difference and our slogan "one man can and will find a way, why not be that man?" underpins our drive.